M Bryborn1, M Adner, L-O Cardell. 1. Laboratory of Clinical and Experimental Allergy, Department of Otorhinolaryngology, Malmö University Hospital, Lund University, Malmö, Sweden. malin.bryborn@oron.mas.lu.se
Abstract
BACKGROUND: IL-4 is believed to play a role in asthma and chronic obstructive pulmonary disease through promotion of eosinophilic inflammation and mucus hypersecretion. Whether IL-4 can induce a direct effect on airway smooth muscle remains unknown. OBJECTIVE: To investigate the effect of IL-4 on airway smooth muscle, focusing on the contractile response to des-Arg9-bradykinin and bradykinin. METHODS: Tracheal segments from murine airways were cultured for 1-8 days in the absence and presence of IL-4. The smooth muscle response induced by des-Arg9-bradykinin and bradykinin was investigated in myographs. Expression levels for the IL-4-, bradykinin B1- and B2-receptors were characterized using RT-PCR. Specific inhibitors were used to study signal changes along the IL-4 receptor- (IL-4R-) coupled mitogen-activated protein (MAP) kinase (MAPK) pathways. RESULTS: IL-4 treatment increased the contractile response to des-Arg9-bradykinin and bradykinin in a concentration- and time-dependent manner. Dexamethasone and the transcriptional inhibitor actinomycin D blocked this effect. c-Jun N-terminal kinase inhibitor SP600125 also blocked the effect of both des-Arg9-bradykinin and bradykinin, whereas p38 inhibitor SB203580 blocked only the former and the MAPKK inhibitor PD098059, only the latter agonist responses. IL-4 treatment increased the mRNA levels representing bradykinin B1- but not B2-receptors. Levels of IL-4R were not altered during culture. CONCLUSION: Long-term exposure to IL-4 increases the contractile response induced by des-Arg9-bradykinin and bradykinin in cultured murine airways. This effect appears to be mediated via an up-regulation of B1-receptors and altered signalling along the MAPK pathways.
BACKGROUND:IL-4 is believed to play a role in asthma and chronic obstructive pulmonary disease through promotion of eosinophilic inflammation and mucus hypersecretion. Whether IL-4 can induce a direct effect on airway smooth muscle remains unknown. OBJECTIVE: To investigate the effect of IL-4 on airway smooth muscle, focusing on the contractile response to des-Arg9-bradykinin and bradykinin. METHODS: Tracheal segments from murine airways were cultured for 1-8 days in the absence and presence of IL-4. The smooth muscle response induced by des-Arg9-bradykinin and bradykinin was investigated in myographs. Expression levels for the IL-4-, bradykinin B1- and B2-receptors were characterized using RT-PCR. Specific inhibitors were used to study signal changes along the IL-4 receptor- (IL-4R-) coupled mitogen-activated protein (MAP) kinase (MAPK) pathways. RESULTS:IL-4 treatment increased the contractile response to des-Arg9-bradykinin and bradykinin in a concentration- and time-dependent manner. Dexamethasone and the transcriptional inhibitor actinomycin D blocked this effect. c-Jun N-terminal kinase inhibitor SP600125 also blocked the effect of both des-Arg9-bradykinin and bradykinin, whereas p38 inhibitor SB203580 blocked only the former and the MAPKK inhibitor PD098059, only the latter agonist responses. IL-4 treatment increased the mRNA levels representing bradykinin B1- but not B2-receptors. Levels of IL-4R were not altered during culture. CONCLUSION: Long-term exposure to IL-4 increases the contractile response induced by des-Arg9-bradykinin and bradykinin in cultured murine airways. This effect appears to be mediated via an up-regulation of B1-receptors and altered signalling along the MAPK pathways.
Authors: Reynold A Panettieri; Michael I Kotlikoff; William T Gerthoffer; Marc B Hershenson; Prescott G Woodruff; Ian P Hall; Susan Banks-Schlegel Journal: Am J Respir Crit Care Med Date: 2007-11-15 Impact factor: 21.405
Authors: Frank Kirstein; William G C Horsnell; Douglas A Kuperman; Xiaozhu Huang; David J Erle; Andreas L Lopata; Frank Brombacher Journal: J Allergy Clin Immunol Date: 2010-06-25 Impact factor: 10.793
Authors: Magnus Starkhammar; Susanna Kumlien Georén; Linda Swedin; Sven-Erik Dahlén; Mikael Adner; Lars Olaf Cardell Journal: PLoS One Date: 2012-02-15 Impact factor: 3.240
Authors: Roberta Araujo Navarro-Xavier; Karina Vieira de Barros; Iracema Senna de Andrade; Zaira Palomino; Dulce Elena Casarini; Vera Lucia Flor Silveira Journal: J Inflamm Res Date: 2016-05-19